POINT Biopharma, a late-stage biopharmaceutical company dedicated to bringing the many benefits of precision radiopharmaceutical therapies to patients with cancer, and Therapeutics Acquisition (d/b/a Research Alliance I) today announced they have entered into a definitive business combination agreement that would value the merged company at $924 million.
The new business will be named POINT Biopharma Global, and its common stock is expected to be listed on the Nasdaq under PNT.
The combined company is expected to receive net proceeds of approximately $300 million at the closing of the transaction, including a $165 million PIPE with participation from RA Capital Management, an affiliate of RACA’s sponsor, as well as Johnson & Johnson Innovation, Surveyor Capital (a Citadel company), Farallon Capital Management, BVF Partners, Boxer Capital, Sphera Healthcare, Woodline Partners, Suvretta Capital, Fairmount Funds, and Perceptive Advisors. Read more.
